Article History
Accepted: 18 November 2021
First Online: 5 January 2022
Competing interests
: Y.T. has received speaking fees and/or honoraria from AbbVie, Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers, Chugai, Eisai, Eli Lilly, Gilead, Mitsubishi-Tanabe and YL Biologics, and received research grants from Abbvie, Asahi-Kasei, Boehringer Ingelheim, Chugai, Corrona, Daiichi-Sankyo, Eisai, Kowa, Mitsubishi-Tanabe and Takeda, and consultant fees from AbbVie, Ayumi, Daiichi-Sankyo, Eli Lilly, GlaxoSmithKline, Sanofi and Taisho. S.N. has received speaking fees and/or honoraria from Asahi-kasei, Astellas, Boehringer Ingelheim, Bristol-Myers, GlaxoSmithKline, Pfizer and Sanofi, and has received research grants from Mitsubishi-Tanabe and Novartis. J.J.O. declares receipt of US patent royalties related to JAK inhibitors and NIH Cooperative Research and Development Agreement with Pfizer. Y.M.L. declares no competing interests.
Free to read: This content has been made available to all.